Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases.
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Bavarian Nordic's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BAVA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BAVA underperformed the Danish Biotechs industry which returned 29.3% over the past year.
Return vs Market: BAVA underperformed the Danish Market which returned 18.6% over the past year.
Price Volatility Vs. Market
How volatile is Bavarian Nordic's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StIs Bavarian Nordic (CPH:BAVA) A Risky Investment?
1 month ago | Simply Wall StWe Wouldn't Rely On Bavarian Nordic's (CPH:BAVA) Statutory Earnings As A Guide
1 month ago | Simply Wall StDid You Manage To Avoid Bavarian Nordic's (CPH:BAVA) Painful 52% Share Price Drop?
Is Bavarian Nordic undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BAVA (DKK190.9) is trading above our estimate of fair value (DKK155.68)
Significantly Below Fair Value: BAVA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BAVA is good value based on its PE Ratio (24.6x) compared to the Biotechs industry average (38.7x).
PE vs Market: BAVA is poor value based on its PE Ratio (24.6x) compared to the Danish market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: BAVA's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: BAVA is good value based on its PB Ratio (1.5x) compared to the XE Biotechs industry average (4.6x).
How is Bavarian Nordic forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BAVA's earnings are forecast to decline over the next 3 years (-17% per year).
Earnings vs Market: BAVA's earnings are forecast to decline over the next 3 years (-17% per year).
High Growth Earnings: BAVA's earnings are forecast to decline over the next 3 years.
Revenue vs Market: BAVA's revenue (18.6% per year) is forecast to grow faster than the Danish market (6.5% per year).
High Growth Revenue: BAVA's revenue (18.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BAVA is forecast to be unprofitable in 3 years.
How has Bavarian Nordic performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BAVA has a high level of non-cash earnings.
Growing Profit Margin: BAVA became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: BAVA has become profitable over the past 5 years, growing earnings by -34.2% per year.
Accelerating Growth: BAVA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BAVA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: BAVA's Return on Equity (5.2%) is considered low.
How is Bavarian Nordic's financial position?
Financial Position Analysis
Short Term Liabilities: BAVA's short term assets (DKK2.6B) exceed its short term liabilities (DKK710.0M).
Long Term Liabilities: BAVA's short term assets (DKK2.6B) do not cover its long term liabilities (DKK3.2B).
Debt to Equity History and Analysis
Debt Level: BAVA's debt to equity ratio (7.8%) is considered satisfactory.
Reducing Debt: BAVA's debt to equity ratio has increased from 2.7% to 7.8% over the past 5 years.
Debt Coverage: BAVA's debt is well covered by operating cash flow (57%).
Interest Coverage: BAVA's interest payments on its debt are well covered by EBIT (16.7x coverage).
What is Bavarian Nordic current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BAVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BAVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BAVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BAVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BAVA's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Chaplin (53yo)
Dr. Paul Chaplin MSc, Ph.D. has been the Chief Executive Officer and President at Bavarian Nordic A/S since May 28, 2014. Dr. Chaplin served as an Executive Vice President of Bavarian Nordic A/S from 2004 ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD0.00) is below average for companies of similar size in the Danish market ($USD1.68M).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
|CEO & President||6.08yrs||ø8.32m||0.13% DKK14.6m|
|CFO & Executive VP||1.67yrs||ø3.94m||0.0043% DKK477.0k|
|COO & Executive VP||3.5yrs||ø3.63m||no data|
|Executive VP & Chief Business Officer||3yrs||ø3.95m||no data|
|Vice President of Investor Relations & Communications||no data||no data||no data|
|Executive VP & Chief Commercial Officer||0.50yr||no data||no data|
|Executive VP & Chief Medical Officer||0.17yr||no data||no data|
Experienced Management: BAVA's management team is considered experienced (2.3 years average tenure).
|Independent Director||10.25yrs||ø668.00k||0.058% DKK6.5m|
|Independent Director||8.25yrs||ø608.00k||0.028% DKK3.1m|
|Independent Deputy Chairman||6.25yrs||ø843.00k||0.015% DKK1.6m|
|Independent Director||4.25yrs||ø747.00k||no data|
|Independent Chairman||6.25yrs||ø1.34m||0.027% DKK3.1m|
|Independent Director||3.25yrs||ø633.00k||no data|
|Independent Director||1.25yrs||no data||no data|
Experienced Board: BAVA's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 81%.
Bavarian Nordic A/S's company bio, employee growth, exchange listings and data sources
- Name: Bavarian Nordic A/S
- Ticker: BAVA
- Exchange: CPSE
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: ø11.145b
- Shares outstanding: 58.38m
- Website: https://www.bavarian-nordic.com
Number of Employees
- Bavarian Nordic A/S
- Philip Heymans Alle 3
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BVNK.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Nov 1998|
|BAVA||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Ordinary Shares||DK||DKK||Nov 1998|
|BV3||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Nov 1998|
|0DPB||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||DKK||Nov 1998|
|BAVAC||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||DKK||Nov 1998|
|BVNR.Y||OTCPK (Pink Sheets LLC)||SPONSORED ADR||US||USD||May 2013|
Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox and monkey pox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola; MVA-BN HPV that is in Phase I clinical trials to treat human papillomavirus; MVA-BN WEV, which is in Phase I clinical trials to treat equine encephalitis; and BN-Brachyury that is in Phase II clinical trials for the treatment of chordoma. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Hellerup, Denmark.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/03 20:48|
|End of Day Share Price||2020/07/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.